AB76. Adipose-derived stem cells improve erectile function through secretion of growth factor in aged rat
Laboratory Study, published in Transl Androl Urol (2014) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Transl Androl Urol (2014)
- Reported sample size
- —
- Source database
- Europe PMC
- PMCID
- PMC4708429
Abstract (original English)
Introduction & objectives Adipose-derived stem cells (ADSCs) have been recently considered promising therapy for erectile dysfunction (ED). However, the mechanism of ADSCs-based therapy remains to be elucidated. The aim of this study was to determine whether transplantation of ADSCs was capable of resolving aging-related ED, and to investigate its underlying mechanisms. Materials & methods Hepatocyte growth factor (HGF), angiopoitein-1 (ANG-1), angiopoitein-2 (ANG-2), insulin-like growth factor (IGF-1), vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) secreted by ADSCs were assessed in vitro. Furthermore, the protective effects of VEGF and bFGF secreted by ADSCs were evaluated in vitro by means of neutralization of VEGF, bFGF or both using CCK-8. Sixteen 24-month-old male Sprague-Dawley rats were used for comparative analysis of 2-week treatment regiments with CM-DiI labeled ADSCs or PBS. Eight additional 5-month-old rats were used as young rats group. At 2-week post-transplantation, all the rats were analyzed for erectile function, cavernous VEGF and bFGF levels, and penile histology. The VEGF and bFGF levels of ADSCs-conditioned medium and penile tissues were determined by an enzyme-linked immunosorbent assay (ELISA). The ratio of maximal intracavernous pressure (ICP) to mean arterial blood pressure (MAP) was measured to evaluate erectile fu
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.